Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading GALT daily closes…
Loading price history…
Pipeline assets
belapectin
Phase 2/3 · Active
Aliases GR-MD-02
Target galectin-3
Indications
prevention of esophageal varices in MASH cirrhosis (NAVIGATE)(Phase 2/3)
MASH with advanced fibrosis (NASH-FX)(Phase 2)
MASH with compensated cirrhosis and portal hypertension (NASH-CX)(Phase 2)
advanced/metastatic head and neck cancer (with PD-1 inhibitor)(Phase 1)
Status note Galectin-3 inhibitor. NAVIGATE Phase 2b/3 (357 patients randomized by Feb 2023) for prevention of esophageal varices in MASH cirrhosis; stage 1 analyzed as stand-alone trial with topline presented December 2024. Filing states NAVIGATE was the company's only active clinical trial and it currently has no plans or funding to undertake another clinical trial. Head and neck cancer Phase 2 commencement dependent on financing (IND filed 2022, Study May Proceed received).
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.